In this edition we mark the sad birthday of 5-year-old Ariel Bibas, the little redhead being held by Hamas with his baby brother and parents. We also want you to know about the courageous stand taken by Ayelet Samerano against the UNWRA secretary-general in Lausanne.
Read about how long can a hostage survive in captivity, about Turkey in NATO, the threats to Israel from Iran and Hezbollah and what the IDF says might happen.
Due to time and schedule issues the delegation's meeting with local companies has been moved from Yokneam to Haifa. The meeting will be held from 9:00 to noon in Greidinger Hall at the Ruth Rappaport Children's Hospital on the Rambam Healthcar Campus in Haifa. For details and registration, contact bshlomo@conexx.org.
Impress Group deploys Zadara Storage to Support Growing VMware Environment Replaces aging storage arrays with Zadara VPSA to address performance, manageability and scalability IRVINE, CA – October 25, 2016 – Zadara™ Storage, the award-winning provider of enterprise-class storage-as-a-service (STaaS) today announced that the Impress Group has replaced their traditional storage arrays with the scalable Zadara VPSA™ Storage Array to support their growing demand for high-performance shared storage. By working with Zadara partner CDC, the Impress Group has architected a storage infrastructure that eliminates prior performance and scalability limitations.
The Impress Group is a leading media group, consisting of a holding company, Impress Holdings, Inc., and 12 operating companies. The company’s storage infrastructure was based on servers with local disk storage and traditional NFS-based shared storage. As the company grew, they recognized they had significant limitations with performance, scalability and manageability. The Impress Group worked closely with their technology partner CDC to find a solution that would enable the company to scale and support their growing demand for VMware storage resources.
After reviewing a variety of industry-leading solutions, the company chose the Zadara VPSA Storage Array to support their growing VMware storage needs. “The Zadara Storage VPSA provides high-availability using complete redundancy and nondisruptive failover,” said Tokuyuki Yokota, engineer, Impress, Professional Works. “The VPSA also leverages industry-leading I/O technologies such as iSER and high-speed SSD caching to optimize VMware performance. We were extremely impressed with the overall performance.
Finally, the centralized management capabilities made the solution an easy decision for us. We have been able to address all of our immediate and future requirements – all while reducing administrative and operating costs.” 1 “At CDC, our goal is to combine best of breed technology to create unique solutions for our customers,” said Yuki Sakamoto, vice president at CDC. “We were pleased to be able to provide the Zadara Storage VPSA architecture to the Impress Group. The Zadara Storage VPSA was the perfect solution to address their challenging storage requirements." “The Impress Group is an excellent example of a customer who experienced the limitations of traditional storage and were able to remove those obstacles by deploying Zadara Storage,” said Dani Naor, vice president, international sales at Zadara Storage. “By properly aligning their storage resources, the Impress Group is now enabling, rather than inhibiting, growth.” Click to Tweet: .@ImpressGroup deploys @ZadaraStorage to Support Growing
Environment – http://bit.ly/ImpressDeploysZadara About Zadara Storage Zadara Storage offers enterprise Storage-as-a-Service (STaaS) through the award-winning Zadara Storage Cloud. It can be deployed at any location (cloud, on-premise or hybrid), supporting any data type (block, file and object) and connecting to any protocol (FC, iSCSI, iSER, NFS, CIFS, S3, Swift). The VPSA™ service provides enterprise SAN and NAS while the ZIOS™ service delivers private object storage. Zadara provides resource isolation, exceptional data security, and management control. Zadara is available via OPaaS (On-Premise-as-a-Service) and through a variety of partners including Amazon Web Services (AWS), Microsoft Azure, Google Cloud Platform and others. Visit www.zadarastorage.com, the Zadara Blog, or on LinkedIn and Twitter. Zadara Storage Media Contacts (A3 Communications): US: Mary Kae Marinac Phone: 978-685-3136 Email: mkm@mkmarinac.com EMEA: Federica Monsone Phone: +44 (0) 1252 875 203 Email: fred.monsone@a3communications.co.uk
Sino-Lite Ltd., an Israeli corporation, has announced the acquisition of Light Instruments Ltd, a leading dental laser manufacturer, previously owned by Syneron Medical Ltd. Owning 100% of Light Instruments' unique technology, Sino-Lite Ltd. has gained access into the prosperous global dental laser market.
"The acquisition of Light Instruments is the first step within a sequence of acquisitions of high technology companies and innovative companies that the group intends to acquire in the Israeli market" said Adv. Eric Ben Mayor - CEO of Sino-Lite Ltd, serving also as Light Instruments Ltd. CEO.
"The new leadership will drive the LiteTouch™ technology brand forward and further develop its valued innovative contribution to the dentistry world" continued Ben-Mayor and added: "Sino-Lite Ltd. shall increase Light Instruments' workforce and expand the variety of high-end advanced Technology Dental Lasers offered, thus affirming its position as a worldwide global leader."
Attracted by Light Instruments' reputation for developing cutting-edge and advanced technology in the dental field, the acquisition marks the latest large investment by Chinese conglomerates in Israeli technology companies.
Light Instruments Ltd's development of a small, simple and portable laser for dental procedures is a sharp contrast from the bulky and complicated equipment common elsewhere.
The dental laser market is one of the biggest potential markets in the coming decade. There is a clear worldwide trend and a willingness from dentists to adopt painless, fast and more efficient solutions. The once-fledging market is rapidly becoming one of the most exciting developments in the healthcare industry.
About Sino-Lite Ltd
Sino-Lite Ltd specializes in the acquisitions, development and management of dental and medical companies worldwide. The company is backed by strong Chinese groups headed by Sino-Ita International Trading Company, headquartered in Beijing China, is the distributor of the Italian brand NewTom Cone Beam 3D Imaging in China and South East Asia. Sino-Ita is a whole solution provider covering the business of high end imaging equipment, high value consumable items, and high value services. Sino-Ita integrates the whole chain from research, sales to service.
For more information, visit http://www.light-inst.com
Semiconductor Today reported today that ColorChip's recent $45 million round of financing is already showing results with ColorChip having begun production of 100G QSFP28 10km transceivers.
In the last few years, the Internet of Things (IoT) has progressed from a fascinating vision, to a must have asset for cost and operational efficiency. In healthcare, wireless technologies are allowing doctors to monitor patients from anywhere at any time.
YOKNEAM ILIT, Israel and MARLBOROUGH, MA – ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), the leading global exoskeleton developer and manufacturer, today announced that the Company sold its 100th personal system this summer, a major milestone indicating growing adoption of personal use of exoskeletons. The Company has also sold more than 150 systems to rehabilitation centers, which are certified by the ReWalk Worldwide Training Standards that train patients for home and community use, and are key to enabling the growth of personal unit sales.
The ReWalk Personal Systems cover a diverse set of end users and geographies. The Company has placed systems across North America, Europe, Asia, Australia, and New Zealand—spanning more than a dozen countries in total. ReWalk Personal systems are being utilized in the homes and communities of law enforcement officers, veterans of the U.S. and other national armed forces, and men and women across a host of professions spanning all ages, races and ethnicities.
"This milestone symbolizes a new era for ReWalk. More public and private insurers are willing to procure and reimburse systems, the technology is evolving at a rapid pace, and there is a growing wealth of clinical evidence outlining the benefits of the technology to the health and well-being of the user," said ReWalk Robotics CEO Larry Jasinski. "We are proud to have passed the 100 personal system mark and continue to work diligently to provide this technology to all eligible users."
"My neurologist told me almost nine years ago that I would never walk again after a debilitating spinal stroke paralyzed me from the waist down," said Rick Batty, a Madison, WI ReWalker. "From that moment on, my mission in life was to stand and walk again — and ReWalk made that happen. The technology also helped me achieve a dramatic turnaround in my everyday health, increasing my upper-body strength and flexibility, and I continue to experience improvements with regular use."
The ReWalk Robotics Personal 6.0 is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury to stand upright and walk. ReWalk is the first exoskeleton system to receive FDA clearance for use in the home as well as in the rehabilitation setting.
For more information, please visit: www.rewalk.com
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk's ability to maintain and grow its reputation and to achieve and maintain market acceptance of its products; ReWalk's ability to achieve reimbursement from third-party payors for its products; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's expectations as to the results of, and the Food and Drug Administration's potential regulatory actions with respect to, ReWalk's mandatory post-market 522 surveillance study; ReWalk's ability to repay its secured indebtedness; ReWalk's ability to improve its products and develop new products; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's ability to secure capital from its at-the-market equity distribution program based on the price range of its ordinary shares and conditions in the financial markets; ReWalk's ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading "Risk Factors" in ReWalk's Annual Report on Form 10-K for the year endedDecember 31, 2015 filed with the U.S. Securities and Exchange Commission and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
YOKNEAM, Israel, September 8, 2016
Innovative device for parent vessel protection during intracranial aneurysm treatment impacting lives around the world
Rapid Medical, a company focused on the development of neurovascular interventional devices, announced today that the Comaneci Adjustable Remodeling Mesh has exceeded 500 successfully treated aneurysms worldwide. This milestone comes only two years after Rapid Medical launched the device in Europe.
The Comaneci is the first-ever adjustable, fully-visible remodeling device. It is intended to provide temporary assistance for coil embolization of intracranial aneurysms. It integrates the advantages of existing adjuvant devices without the risk of parent vessel occlusion during coiling procedure or the need for long-term antiplatelet medication in case of permanent stenting.
“With traditional balloon remodeling techniques, preserving constant flow into intracranial arteries is impossible. The availability of a fully-visible device that permits constant flow during the procedure was previously non-existent,” said Prof. Dr. Luca Remonda, Head of Neuroradiology, at Kantonsspital Aarau, Switzerland. “The Comaneci has become a standard tool in our practice and many of our patients have experienced its benefits.”
The Comaneci uses Rapid Medical’s FlexiBraid technology, a unique and proprietary braiding capability that allows the first fully-visible, controllable device that can be adjusted by the physician to perfectly fit the dimensions of parent vessels and the aneurysm neck.
Three versions of the device are currently available; each designed to treat aneurysms in different anatomical locations. The Comaneci and Comaneci Petit versions are delivered through a microcatheter with an internal diameter of 0.021″ and the Comaneci 17 version through a micorcatheter with an internal diameter of 0.0165″.
“We are very pleased with the rapid adoption of the Comaneci device, which is becoming a preferred tool in neurovascular practice,” said Eitan Havis, VP of Sales and Marketing. “We believe the combination of adjustability, visibility and compliance offered by the Comaneci is a critical part in successful aneurysm treatment.”
The Comaneci family of devices are available for sale in Europe and Israel. Rapid Medical plans to launch the Comaneci in additional regions in the coming months.
About Rapid Medical
Rapid Medical is the developer of game-changing devices for endovascular treatments. This includes TIGERTRIEVER, the first-ever controllable, fully-visible retrievable stent, and Pele, a large lumen distal access catheter. TIGERTRIEVER, Comaneci, and Pele are CE marked for use in Europe. More information is available at http://www.rapid-medical.com.
Contact:
Eitan Havis, VP of Sales and Marketing
Rapid Medical
eitan@rapid-medical.com
+972-72-250-3331
